Why is Abbott Laboratories stock up 1.6% today?

Traders Union
All News
Stocks
Abbott laboratories rises 1.62% today

Highlights

Abbott Laboratories raised its 2026 adjusted diluted EPS guidance to $5.45–$5.60 following a strong second quarter.
Ongoing growth in diagnostics, medical devices, and strategic acquisitions drove sales and supported $2.1 billion in shareholder returns.
Shares trade with strong bullish momentum near $109.06, with a projected five-session range of $104.47 to $113.65 and a 78% probability of further upside.

Shareholder returns and EPS upgrade boost sentiment as segment growth leads

Abbott Laboratories reported strong second-quarter results and raised its full-year 2026 adjusted diluted EPS guidance to $5.45–$5.60. The company also reaffirmed its comparable sales growth outlook and credited growth in diagnostics, medical devices, and strategic acquisitions as drivers. During the quarter, Abbott returned $2.1 billion to shareholders through dividends and buybacks, with ongoing restructuring actions and changes in EPS calculation noted in its filings.

Anton Kharitonov, expert at Traders Union, notes that the recent uptrend in Abbott Laboratories is largely fueled by upbeat earnings guidance and aggressive buybacks. However, he remains wary of structural risks, as the long-term technical setup is still bearish despite a short-term surge above key moving averages. Kharitonov sees elevated intraday volatility and overbought indicators as red flags for potential pullbacks. He points to heavy positioning and sentiment extremes as reasons to question durability of the rally. "While the current optimism is tempting, traders should beware chasing at stretched levels near $109 — the risk of a reversal is pronounced if momentum fades."

Viktoras Karapetjanc, expert at Traders Union, highlights the strong fundamental backdrop for Abbott Laboratories, driven by robust results, a confident 2026 EPS outlook, and continued shareholder returns. He argues that momentum remains clearly with the bulls, as critical sales drivers and strategic acquisitions reinforce the company's growth story. Karapetjanc points out that market participants have responded positively, resulting in price leadership above all major moving averages. "With the bullish structure intact and guidance upgrades, I expect further growth toward the $113.65 target as opportunities for upside continue to emerge."

Parshwa Turakhiya, analyst, observes that sentiment and technicals support a bullish momentum setup for ABT in the coming sessions. He emphasizes the overbought readings and elevated volatility, which signal strong but potentially unstable buying interest. Turakhiya believes the $109.25 resistance presents a make-or-break moment for follow-through. "Short-term traders may find tactical opportunities if momentum sustains, but I would watch for a possible sharp move if support at $108.74 breaks."

Short-term bullish surge confronts overbought signals and long-term bearish tilt

Abbott Laboratories is trading above all key moving averages, with the price at $109.06 exceeding the MA-20 ($97.03), MA-50 ($92.14), and MA-200 ($108.74). This configuration signals strong bullish momentum in the short and medium term, even as a long-term bearish structure persists due to the MA-50 versus MA-200 alignment. Immediate technical boundaries are established by the near-term support at $108.74 and resistance at the recent week high of $109.25. Momentum indicators, including MACD, ADX, and the Awesome Oscillator, confirm a broad buy outlook. Overbought conditions are present with the RSI at 73.33, CCI at 160.24, and Stochastic RSI at 100, while BBP at 9.14 signals strong buyer activity and stretched sentiment. Intraday volatility is elevated at 2.62%, and price action remains close to session highs.

Earlier, analysts noted that Abbott Laboratories exhibited robust short- and medium-term bullish momentum despite the persistence of long-term resistance. With the latest earnings beat reinforcing buying interest and overbought conditions intensifying, traders should monitor for a decisive move above $109.25 as a trigger for a renewed leg higher.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.